Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HER2+ metastatic breast cancer. In this educational program, these experts discuss evolving treatment options for HER2+ metastatic breast cancer, with a focus on frontline and maintenance settings. Topics include emerging combination induction therapies and sequencing strategies, with an emphasis on maintenance options and balancing disease control with quality of life.
This educational activity is an archive of the live symposium held on March 5, 2026.
Target Audience
This online educational activity is primarily directed toward medical oncologists, surgical oncologists, advanced practice providers, oncology nurses, oncology pharmacists, and other health care providers involved in the diagnosis and management of patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess emerging clinical evidence supporting current and novel treatment strategies in the frontline setting for HER2+ MBC
- Develop individually tailored induction and maintenance regimens based on patient and disease characteristics
- Identify and manage adverse events associated with current frontline HER2-targeted therapies
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GSK, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Reshma L. Mahtani, DO
Medical Oncologist
Chief of Breast Medical Oncology
Baptist Health Miami Cancer Institute
Miami, FL
Disclosures: Consultant: Agendia, Arvinas, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Hologic, Lilly, Novartis, Pfizer, Sermonix, Stemline; Grant/Research Support: Gilead Sciences
Heather McArthur, MD, MPH
Professor of Internal Medicine Clinical
Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
Dallas, TX
Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck
Paolo Tarantino, MD, PhD
Clinical Fellow Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Menarini/Stemline, Novartis, Roche; Grant/Research Funding: AstraZeneca
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
